Table 5.
Pharmacokinetic parameters of MPI8 after IV and oral administration of MPI8 sulfonate to rats (data derived from NCA).
| Parameters | Mean ± SD | |
|---|---|---|
| i.v. (5 mg/kg) (n = 3) | Oral (50 mg/kg) (n = 3) | |
| Cmax | - | 600.67 ± 75.04 |
| Tmax | - | 2.17 ± 0.58 |
| AUC0−10 h (h∙ng/mL) | 613.06 ± 15.40 | 1177.26 ± 290.10 |
| AUC0−inf (h∙ng/mL) | 617.84 ± 15.68 | 1181.62 ± 287.53 |
| T1/2 (h) | 2.75 ± 0.53 | 1.22 ± 0.46 |
| CL/F (mL/h/kg) | 6606.93 ± 213.82 | 43,984.84 ± 10,389.13 |
| Vz/F (ml/kg) | 26,324.66 ± 5882.81 | 81,570.63 ± 48,751.79 |
| MRT (h) | 0.54 ± 0.10 | 2.52 ± 0.16 |
| F (%) | - | 15.76 ± 4.35 |
Cmax: maximum drug concentration; Tmax: time to reach maximum drug concentration; AUC0−10h: the area under the plasma concentration–time curve during the period of measurable observation; AUC0−inf: the area under the plasma concentration–time curve extrapolated to infinity; T1/2: terminal elimination half-life; CL/F: apparent clearance; Vz/F: the apparent volume of distribution during the terminal phase; MRT: mean residence time; F: oral bioavailability; -: not applicable.